Impact of COVID19 on Asthma

Overview

The COVID19 pandemic is having an immeasurable impact on the economy and on morbidity and mortality. Knowledge and scientific evidence about this disease is advancing rapidly, but it is not yet known whether asthmatic patients suffering from COVID19 have an exacerbation of asthma, or whether this viral infection has an impact on control and lung function in the short to medium term. The aim of this study is to define the changes that occur in these two parameters in asthmatic patients suffering from COVID19. To this end, asthmatic patients who have suffered a SARS-CoV-2 infection and who have required an emergency consultation or hospitalisation will be collected in a pneumology consultation and matched by age, sex and severity of asthma with a group that has not suffered the same. Both will be followed for one year, and lung function will be tested at six months and exacerbations and changes in ACT during the following year. These data are intended to improve the available knowledge on the impact of IDVC19 on asthma patients with a view to making appropriate recommendations, prevention and treatment adjustments in line with the results obtained.

Full Title of Study: “Impact of COVID19 on Lung Function and Control of Asthma Patients”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 1, 2023

Interventions

  • Diagnostic Test: spirometry
    • Lung function test: pre and post bronchodilator spirometry
  • Other: Asthma control test
    • Asthma control test

Arms, Groups and Cohorts

  • Asthma and COVID19 infection
    • Asthma and COVID19 infection
  • Asthma without COVID19 infection
    • Asthma and COVID19 infection

Clinical Trial Outcome Measures

Primary Measures

  • Asthma control
    • Time Frame: 6 months
    • Change in score of Asthma Control Test (ACT). Min 5 máx 25 (the higher score indicates better control)

Secondary Measures

  • Asthma function
    • Time Frame: 6 months
    • Change in FEV1 (Forced expiratory volume in one second)

Participating in This Clinical Trial

Inclusion Criteria

  • 12 -80 years – Asthma diagnosis according to guidelines – Follow up on asthma clinics in one of the participant hospitals Exclusion Criteria:

  • Other severe respiratory condition independent of asthma

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
  • Collaborator
    • Sociedad Española de Neumología y Cirugía Torácica
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Elena Curto, MD, 699877357, ecurto@santpau.cat

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.